Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 147,543 shares, a decrease of 44.5% from the April 15th total of 265,805 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average daily volume of 38,559 shares, the days-to-cover ratio is presently 3.8 days.

Hedge Funds Weigh In On Estrella Immunopharma

A number of institutional investors have recently added to or reduced their stakes in ESLA. Renaissance Technologies LLC raised its holdings in Estrella Immunopharma by 1,045.7% in the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after purchasing an additional 111,779 shares in the last quarter. Marshall Wace LLP bought a new position in Estrella Immunopharma in the fourth quarter worth $88,000. XTX Topco Ltd raised its holdings in Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares in the last quarter. Quadrature Capital Ltd bought a new position in Estrella Immunopharma in the fourth quarter worth $43,000. Finally, State Street Corp raised its holdings in Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares in the last quarter. Institutional investors own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ESLA. Wall Street Zen raised Estrella Immunopharma from a “sell” rating to a “hold” rating in a research note on Saturday, January 31st. D. Boral Capital reiterated a “buy” rating and issued a $8.00 price objective on shares of Estrella Immunopharma in a report on Monday, February 9th. Finally, Weiss Ratings upgraded Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Trading Up 0.9%

NASDAQ ESLA traded up $0.01 on Monday, hitting $1.12. The company’s stock had a trading volume of 21,435 shares, compared to its average volume of 155,182. Estrella Immunopharma has a 52-week low of $0.78 and a 52-week high of $3.15. The company’s 50-day simple moving average is $1.35 and its 200 day simple moving average is $1.50. The firm has a market cap of $47.79 million, a P/E ratio of -3.20 and a beta of 0.97.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.17. On average, research analysts forecast that Estrella Immunopharma will post -0.39 EPS for the current fiscal year.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.